Stemline Therapeutics is a clinical-stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSC) as well as the tumor bulk. Among Stemline’s drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients. The Discovery Platform called StemScreen identifies new compounds that target and kill CSC. Stemline’s remarkable portfolio includes intellectual property with the earliest filings in the CSC field covering CSC-directed therapeutics, diagnostics, and drug discovery. For more information, visit the company’s Web site at www.stemline.com.